 Interferon-alpha
"Interferon-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways.
| Descriptor ID |
D016898
|
| MeSH Number(s) |
D12.644.276.374.440.890.250 D12.644.276.718.500.250 D12.776.467.374.440.890.250 D12.776.467.718.500.250 D23.529.374.440.890.250 D23.529.718.500.250
|
| Concept/Terms |
Interferon-alpha- Interferon-alpha
- Interferon alpha
- Interferon Alfa
- Interferon, Lymphoblastoid
- Lymphoblastoid Interferon
- Interferon, Leukocyte
- Leukocyte Interferon
- Interferon, Lymphoblast
- Lymphoblast Interferon
- alpha-Interferon
- alpha Interferon
- Interferon, alpha
Interferon alpha-17- Interferon alpha-17
- Interferon alpha 17
- Interferon alpha-T
- Interferon alpha T
- LeIF I
- Interferon alpha-88
- Interferon alpha 88
Interferon alpha-7- Interferon alpha-7
- Interferon alpha 7
- LeIF J
- Interferon alpha-J
- Interferon alpha J
Interferon alpha-5- Interferon alpha-5
- Interferon alpha 5
- Interferon alpha5
- IFN-alpha5
- IFN alpha5
Interferon alpha-2- Interferon alpha-2
- Interferon alpha 2
- LeIF A
- Interferon alpha-A
- Interferon alpha A
- Interferon-alpha 2
- 2, Interferon-alpha
- IFN-alpha 2
- IFN-alpha-2
|
Below are MeSH descriptors whose meaning is more general than "Interferon-alpha".
Below are MeSH descriptors whose meaning is more specific than "Interferon-alpha".
This graph shows the total number of publications written about "Interferon-alpha" by people in UAMS Profiles by year, and whether "Interferon-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 1 | 1 | | 2020 | 0 | 2 | 2 | | 2019 | 1 | 0 | 1 | | 2018 | 0 | 1 | 1 | | 2017 | 1 | 1 | 2 | | 2016 | 0 | 2 | 2 | | 2015 | 1 | 1 | 2 | | 2014 | 1 | 1 | 2 | | 2012 | 0 | 2 | 2 | | 2011 | 0 | 1 | 1 | | 2010 | 2 | 1 | 3 | | 2009 | 1 | 0 | 1 | | 2006 | 1 | 1 | 2 | | 2005 | 2 | 3 | 5 | | 2004 | 2 | 1 | 3 | | 2003 | 2 | 0 | 2 | | 2000 | 2 | 1 | 3 | | 1999 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Interferon-alpha" by people in Profiles over the past ten years.
-
Wang X, Tang Q, Li H, Jiang H, Xu J, Bergquist R, Qin Z. Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis. Int J Infect Dis. 2023 May; 130:147-152.
-
Tripathi H, Al-Darraji A, Abo-Aly M, Peng H, Shokri E, Chelvarajan L, R Donahue R, Levitan BM, Gao E, Hernandez G, Morris AJ, Smyth SS, Abdel-Latif A. Autotaxin inhibition reduces cardiac inflammation and mitigates adverse cardiac remodeling after myocardial infarction. J Mol Cell Cardiol. 2020 12; 149:95-114.
-
Houssein M, Fatfat M, Habli Z, Ghazal N, Moodad S, Khalife H, Khalil M, Gali-Muhtasib H. Thymoquinone synergizes with arsenic and interferon alpha to target human T-cell leukemia/lymphoma. Life Sci. 2020 Jun 15; 251:117639.
-
Novak T, Hall MW, McDonald DR, Newhams MM, Mistry AJ, Panoskaltsis-Mortari A, Mourani PM, Loftis LL, Weiss SL, Tarquinio KM, Markovitz B, Hartman ME, Schwarz A, Junger WG, Randolph AG. RIG-I and TLR4 responses and adverse outcomes in pediatric influenza-related critical illness. J Allergy Clin Immunol. 2020 06; 145(6):1673-1680.e11.
-
Cao XX, Niu N, Sun J, Cai H, Wang FD, Wang YN, Duan MH, Zhou DB, Li J. Clinical and positron emission tomography responses to long-term high-dose interferon-a treatment among patients with Erdheim-Chester disease. Orphanet J Rare Dis. 2019 01 10; 14(1):11.
-
Zhao AL, Wang YN, Wang FD, Niu N, Sun J, Mao YY, Zhou DB, Li J, Cao XX. Successful Treatment of Erdheim-Chester Disease With Coronary Artery Involvement. Can J Cardiol. 2018 12; 34(12):1688.e9-1688.e11.
-
Cao XX, Niu N, Sun J, Zhou DB, Li J. Efficacy of intermediate-dose cytarabine in central nervous system-relapsed wild-type BRAF Erdheim-Chester disease. Ann Hematol. 2018 Jan; 97(1):185-187.
-
Thandassery RB, Kaabi SA, Soofi ME, Tharian B, Singh R. Noninvasive serum models to predict significant liver related events in chronic hepatitis C. Hepatol Int. 2017 Jul; 11(4):401-408.
-
Yeruva L, Spencer NE, Saraf MK, Hennings L, Bowlin AK, Cleves MA, Mercer K, Chintapalli SV, Shankar K, Rank RG, Badger TM, Ronis MJ. Formula diet alters small intestine morphology, microbial abundance and reduces VE-cadherin and IL-10 expression in neonatal porcine model. BMC Gastroenterol. 2016 Mar 22; 16:40.
-
Cao XX, Sun J, Li J, Zhong DR, Niu N, Duan MH, Liang ZY, Zhou DB. Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults. Ann Hematol. 2016 Apr; 95(5):745-50.
-
Duarte-Rojo A, Fischer SE, Adeyi O, Zita D, Deneke MG, Selzner N, Chen L, Malespin M, Cotler SJ, McGilvray ID, Feld JJ. Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C. J Viral Hepat. 2016 May; 23(5):340-7.
-
Bratton EM, Knutsen-Larson S, Durairaj VD, Gregory DG, Mellette JR. Combination topical therapy for conjunctival primary acquired melanosis with atypia and periocular lentigo maligna. Cornea. 2015 Jan; 34(1):90-3.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|